Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mercedes Colorado

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Leukemia|February 2, 2021
Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemiaBruno Paiva, María-Belen Vidriales, Amparo Sempere, et al.
Leukemia|October 20, 2020
Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?David Martínez-Cuadrón, Josefina Serrano, Cristina Gil, et al.
Transplantation and Cellular Therapy|February 16, 2025
Autologous or Allogeneic Hematopoietic Stem Cell Transplantation as Front-Line Treatment for Adult Secondary Acute Myeloid Leukemia Patients: The PETHEMA Registry ExperienceJosefina Serrano, David Martínez-Cuadrón, Cristina Gil, et al.
Transplantation and Cellular Therapy|April 10, 2021
Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA StudyEduardo Rodríguez-Arbolí, David Martínez-Cuadrón, Rebeca Rodríguez-Veiga, et al.
Blood Advances|November 18, 2021
Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry studyDavid Martínez-Cuadrón, Juan E Megías-Vericat, Josefina Serrano, et al.
Hematological Oncology|January 9, 2026
CEBPA-bZIP Mutations in AML Patients Treated With Non-Intensive Therapy: A Study by the Spanish PETHEMA RegistryEsther Prados de la Torre, Josefina Serrano, Eva Barragán, et al.
Bone Marrow Transplantation|May 7, 2026
Impact of molecular profiling in patients with acute myeloid leukemia undergoing allogeneic transplantation in first remission: a study by the PETHEMA groupRafael Colmenares, Eva Barragán, Rebeca Rodríguez-Veiga, et al.
Cancers|February 25, 2023
Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase InhibitorsLucía Pérez-Lamas, Alejandro Luna, Concepción Boque, et al.
Cancer|January 3, 2025
Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry studyPilar Lloret-Madrid, Blanca Boluda, Joaquín Martínez-López, et al.
Haematologica|July 16, 2026
Co-mutation signatures are age-dependent and impact the prognosis in <i>NPM1</i>-mutated acute myeloid leukemia: a PETHEMA multicenter studyJosé Vicente Gil, Claudia Sargas, Rosa Ayala, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Leukemia|February 2, 2021
Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemiaBruno Paiva, María-Belen Vidriales, Amparo Sempere, et al.
Leukemia|October 20, 2020
Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?David Martínez-Cuadrón, Josefina Serrano, Cristina Gil, et al.
Transplantation and Cellular Therapy|February 16, 2025
Autologous or Allogeneic Hematopoietic Stem Cell Transplantation as Front-Line Treatment for Adult Secondary Acute Myeloid Leukemia Patients: The PETHEMA Registry ExperienceJosefina Serrano, David Martínez-Cuadrón, Cristina Gil, et al.
Transplantation and Cellular Therapy|April 10, 2021
Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA StudyEduardo Rodríguez-Arbolí, David Martínez-Cuadrón, Rebeca Rodríguez-Veiga, et al.
Blood Advances|November 18, 2021
Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry studyDavid Martínez-Cuadrón, Juan E Megías-Vericat, Josefina Serrano, et al.
Hematological Oncology|January 9, 2026
CEBPA-bZIP Mutations in AML Patients Treated With Non-Intensive Therapy: A Study by the Spanish PETHEMA RegistryEsther Prados de la Torre, Josefina Serrano, Eva Barragán, et al.
Bone Marrow Transplantation|May 7, 2026
Impact of molecular profiling in patients with acute myeloid leukemia undergoing allogeneic transplantation in first remission: a study by the PETHEMA groupRafael Colmenares, Eva Barragán, Rebeca Rodríguez-Veiga, et al.
Cancers|February 25, 2023
Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase InhibitorsLucía Pérez-Lamas, Alejandro Luna, Concepción Boque, et al.
Cancer|January 3, 2025
Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry studyPilar Lloret-Madrid, Blanca Boluda, Joaquín Martínez-López, et al.
Haematologica|July 16, 2026
Co-mutation signatures are age-dependent and impact the prognosis in <i>NPM1</i>-mutated acute myeloid leukemia: a PETHEMA multicenter studyJosé Vicente Gil, Claudia Sargas, Rosa Ayala, et al.
Pageof 5